Over the past few weeks biotech giant Amgen has been hit with delays for getting a potentially blockbuster drug to market; 15 states filed a federal lawsuit against the company; and a new study shows its anemia drug, Aranesp, may be causing more harm than good for some patients.

The first hit for the compamy was the FDA extending its review period for approving the company’s experimental osteoporosis drug denosumab...

Join our Membership to get the full story.

Are you a current Member? Sign In